COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V9HC
|
|||
| Drug Name |
Darunavir + cobicistat
|
|||
| Synonyms |
Prezcobix; Prezista + GS-9350
|
|||
| Drug Type |
Combination drug
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) | Phase 3 | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL
|
||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | COVID-19 3C-like protease (3CLpro) | Target Info | Inhibitor | [2] |
| Darunavir/cobicistat blocks viral replication of SARS-CoV-2 via inhibiting the 3C-like protease (3CLpro). | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | ClinicalTrials.gov (NCT04252274) Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19 | |||
| 2 | Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.